Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Huawei Chen

Showing results (131-140 of 150) with videos related to

Pageof 15
Sort By:
Plos One|July 24, 2018
BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer and confers sensitivity to BET inhibitorsGarrett W Rhyasen, Yi Yao, Jingwen Zhang, et al.
ACS Chemical Biology|September 17, 2019
Rapid Identification of Novel Allosteric PRC2 InhibitorsJon A Read, Jonathan Tart, Philip B Rawlins, et al.
Journal of Medicinal Chemistry|December 3, 2014
Discovery of potent KIFC1 inhibitors using a method of integrated high-throughput synthesis and screeningBin Yang, Michelle L Lamb, Tao Zhang, et al.
Advanced Materials (Deerfield Beach, Fla.)|December 28, 2018
Self-Assembled Networked PbS Distribution Quantum Dots for Resistive Switching and Artificial Synapse Performance Boost of MemristorsXiaobing Yan, Yifei Pei, Huawei Chen, et al.
Journal of Medicinal Chemistry|December 23, 2016
Design, Synthesis, and Biological Activity of Substrate Competitive SMYD2 InhibitorsScott D Cowen, Daniel Russell, Leslie A Dakin, et al.
Bioorganic & Medicinal Chemistry Letters|June 26, 2012
Discovery of novel benzylidene-1,3-thiazolidine-2,4-diones as potent and selective inhibitors of the PIM-1, PIM-2, and PIM-3 protein kinasesLes A Dakin, Michael H Block, Huawei Chen, et al.
Cancer Cell|March 14, 2018
BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination DeficiencyChaoyang Sun, Jun Yin, Yong Fang, et al.
NPJ Precision Oncology|December 27, 2022
The landscape of therapeutic vulnerabilities in EGFR inhibitor osimertinib drug tolerant persister cellsSteven W Criscione, Matthew J Martin, Derek B Oien, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Potent and Selective Inhibitors of CK2 Kinase Identified through Structure-Guided HybridizationJames E Dowling, Claudio Chuaqui, Timothy W Pontz, et al.
Journal of Medicinal Chemistry|February 13, 2013
Discovery and optimization of a novel series of potent mutant B-Raf(V600E) selective kinase inhibitorsMelissa M Vasbinder, Brian Aquila, Martin Augustin, et al.
Pageof 15

Showing results (131-140 of 150) with videos related to

Sort By:
Pageof 15
Plos One|July 24, 2018
BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer and confers sensitivity to BET inhibitorsGarrett W Rhyasen, Yi Yao, Jingwen Zhang, et al.
ACS Chemical Biology|September 17, 2019
Rapid Identification of Novel Allosteric PRC2 InhibitorsJon A Read, Jonathan Tart, Philip B Rawlins, et al.
Journal of Medicinal Chemistry|December 3, 2014
Discovery of potent KIFC1 inhibitors using a method of integrated high-throughput synthesis and screeningBin Yang, Michelle L Lamb, Tao Zhang, et al.
Advanced Materials (Deerfield Beach, Fla.)|December 28, 2018
Self-Assembled Networked PbS Distribution Quantum Dots for Resistive Switching and Artificial Synapse Performance Boost of MemristorsXiaobing Yan, Yifei Pei, Huawei Chen, et al.
Journal of Medicinal Chemistry|December 23, 2016
Design, Synthesis, and Biological Activity of Substrate Competitive SMYD2 InhibitorsScott D Cowen, Daniel Russell, Leslie A Dakin, et al.
Bioorganic & Medicinal Chemistry Letters|June 26, 2012
Discovery of novel benzylidene-1,3-thiazolidine-2,4-diones as potent and selective inhibitors of the PIM-1, PIM-2, and PIM-3 protein kinasesLes A Dakin, Michael H Block, Huawei Chen, et al.
Cancer Cell|March 14, 2018
BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination DeficiencyChaoyang Sun, Jun Yin, Yong Fang, et al.
NPJ Precision Oncology|December 27, 2022
The landscape of therapeutic vulnerabilities in EGFR inhibitor osimertinib drug tolerant persister cellsSteven W Criscione, Matthew J Martin, Derek B Oien, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Potent and Selective Inhibitors of CK2 Kinase Identified through Structure-Guided HybridizationJames E Dowling, Claudio Chuaqui, Timothy W Pontz, et al.
Journal of Medicinal Chemistry|February 13, 2013
Discovery and optimization of a novel series of potent mutant B-Raf(V600E) selective kinase inhibitorsMelissa M Vasbinder, Brian Aquila, Martin Augustin, et al.
Pageof 15